Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
PMLiVE9h
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...
Nasdaq4d
Gilead's Seladelpar Gets Conditional European Approval For Primary Biliary Cholangitis Treatment
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...
Daily1d
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
Nasdaq4d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
U.S. Indication for Livdelzi Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate ...
BioSpace8h
Mirum Establishes Liver Expertise With First FDA Nod for ‘Very Rare’ Disease
Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...
The Pharma Letter3d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
stocknews1h
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Le Lézard8h
Mirum's CTEXLItm (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLItm (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous ...